This study provides evidence that metformin treatment produces artery-specific gene expression effects. The genes whose expression was modulated with metformin do not appear to have a clear connection with its known mechanisms of action.
Introduction
Based on current recommendations from the American Diabetes Association, metformin is a first-line treatment for type 2 diabetes mellitus (T2D) along with diet and exercise. 1, 2 Metformin lowers blood glucose concentrations by reducing basal hepatic glucose production and increasing insulin sensitivity in skeletal muscle. 3 In addition to being extensively used in the treatment of T2D, the use of metformin as a preventative therapy in patients at risk for developing overt T2D is also becoming increasingly widespread. In this regard, data from the Diabetes Prevention Program demonstrate that use of metformin lowered the incidence of T2D by 31% in nondiabetic insulin-resistant subjects. 4 Despite the prevalent use of metformin for the treatment and prevention of T2D, the vascular effects of metformin have not been fully elucidated. Increased knowledge in this area is important in light of the established link between diabetes and vascular complications. [5] [6] [7] Although several studies provide evidence that metformin improves vascular function, [8] [9] [10] [11] this is not a universal finding. 12, 13 We recently examined the effect of metformin treatment on insulin-stimulated dilation in isolated skeletal muscle feed arteries and arterioles from Otsuka Long-Evans Tokushima Fatty (OLETF) rats, 13 a well-established rodent model of obesity, insulin resistance, and T2D. 14 In contrast to our hypothesis, metformin treatment did not enhance vasodilatory responses to insulin in skeletal muscle resistance arteries despite an improvement in glycemic control. 13 As in previous studies from our group, lack of changes in vasomotor function in response to an intervention does not imply an absence of a vascular phenotypic effect at the molecular level. [15] [16] [17] As such, to gain further insights into the impact of metformin on the vasculature, we assessed transcriptional profiles in skeletal muscle resistant arteries from the OLETF rats utilized in our previous study. 13 Specifically, we performed a transcriptome-wide RNA sequencing (RNA-Seq) analysis in the feed arteries and second branch order arterioles in the soleus, gastrocnemius, and diaphragm muscles in metformin-treated (via drinking water for 12 weeks) versus untreated OLETF rats. Owing to the systemic nature of its administration, we hypothesized that the gene expression effects of metformin would be largely uniform across vascular beds examined. To more specifically evaluate the effects of metformin on the endothelium, the same RNA-Seq analysis approach was employed in aortic endothelial cell scrapes. Given that metformin's mechanisms of action appear to involve activation of AMP-activated protein kinase (AMPK), 18 mitochondrial complex 1 inhibition, 19 and inhibition of mitochondrial glycerophosphate dehydrogenase (GPD2), 20 we postulated that differentially expressed genes by metformin treatment would be largely related to these pathways.
Material and methods

Animals and experimental design
Male OLETF rats (n ¼ 19) were obtained at four weeks of age (Japan SLC, Hamamatsu, Shizuoka, Japan). The OLETF rat possesses a mutated cholestykinin-1 receptor, causing hyperphagic obesity and insulin resistance. 14 Animal housing conditions, body composition measurements, food intake assessment, metformin treatment regimens, blood parameter measurements, and sacrifice/tissue harvesting procedures have been described in previous manuscripts from our laboratory. 13, 21, 22 The University of Missouri Animal Care and Use Committee approved all study protocols.
Isolation of arteries and RNA sequencing
The gastrocnemius-plantaris-soleus muscle complex and diaphragm were harvested and pinned down in a Petri dish containing an RNA-stabilizing agent (RNAlater; Ambion, Austin, TX, USA). A total of seven arteries of interest were prepared for RNA-Seq analysis: gastrocnemius feed artery (GFA), soleus feed artery (SFA), diaphragm feed artery (DFA), white gastrocnemius second branch order arteriole (WG2a), red gastrocnemius second branch order arteriole (RG2a), soleus second branch order arteriole (S2a), and diaphragm second branch order arteriole (D2a). The reader is referred to our recent publications for a visual of the anatomic location and structure of gastrocnemius and soleus vascular network. 17, 23 RNA extraction, RNA quality control, library preparation, and RNA-seq were performed as described previously. 16, 24 
Statistical analysis
The analysis of the RNA-Seq data was carried out for all eight vessel types as described previously. 24 Adjustment for multiple comparisons was performed using the false discovery rate (FDR) method of Benjamini and Hochberg. 25 We chose 15% as our FDR threshold for statistical significance. For all lists of differentially expressed genes, it should be noted that statistical evidence is not intended to prove that the gene with the highest fold change has a smaller P value than the gene with the second highest fold change. Gene ontology (GO) analyses were subsequently carried out on the gene lists for overrepresentation of biological process and molecular function, as we previously described. 15 Between-group differences for all descriptive variables were determined by independent t-test, for which statistical significance was accepted at P < 0.05. Figure 1 summarizes animal characteristic data from the rats used in the current RNA-Seq analysis, which was a subset of the rats used in our prior investigations. 13, 21, 22 As shown, compared to untreated rats, metformin-treated rats were smaller, leaner, and exhibited lower levels of HbA1c. The trend for reduction in fasting glucose with metformin did not reach statistical significance (p ¼ 0.08). The results of the single-end 50bp sequencing reads yielded $175-200 million useable reads per lane (14-17 million reads per RNA-seq sample). A full list of differentially expressed genes between metformin-treated and untreated rats for all arteries in which genes were affected is provided in Supplemental Dataset 1. Results from the GO analysis are provided in Supplemental Dataset 2.
Results
For the eight comparisons reported involving untreated versus metformin treated across eight arteries, the average ERCC Spike-in (Set B, n ¼ 10 probes) empirical FDR (eFDR) was 2.9% at the nominal FDR cutoff of 15% (mean fold ¼ 1.25), while for the putative housekeeping genes the average was 6.2% (mean fold ¼ 0.99). Collectively, these findings strongly support the methodology used because, on average, the fold changes for these controls are approximately equal to 1 and the eFDR is approximately equal to the target FDR (15%). However, there was more intercomparison variability than we have observed in past analysis of data arising from this broader set of experiments. Although we do not have a good explanation for this, it is possible that a portion of this variability is related to subtle between-animal differences in metformin dosing through drinking water. This impact appeared to be most pronounced in the RG2a group, which had an ERCC Spikein eFDR of 23%. All other groups had an eFDR of 0% based on the spike-ins. Figure 2 displays the number of genes altered with metformin across all eight arteries examined. The greatest number of differentially expressed genes with metformin was found in the RG2a (93 genes; Table 1 ), followed by the D2a (62 genes; Table 2 ) and S2a (15 genes; Table 3 ). There were two genes differentially expressed with metformin in aortic endothelial cells (LETMD1 and HMGCS2, both downregulated), one gene differentially expressed with metformin in the GFA (BLNK, downregulated), and no genes differentially expressed with metformin in the SFA, DFA, and WG2a. No single gene was altered by metformin across all vessels examined. Expression of PCM1 was increased with metformin in both the RG2a and D2a, and JAG1 was increased in both RG2a and S2a. Expression of SYNGR3 was also altered by metformin in both the RG2a and S2a but in opposite directions (decrease in RG2a and increase in S2a).
Discussion
Metformin treatment for prediabetes and T2D is widespread. Metformin reduces blood glucose concentrations by lowering basal hepatic glucose production and exerting insulin-sensitizing effects in skeletal muscle. 3 In addition, metformin has beneficial effects on the vasculature [8] [9] [10] [11] and its use is associated with decreased cardiovascular events. 3 The purpose of this study was to gain a better understanding of the effects of metformin treatment on vascular gene expression using the obese insulin-resistant OLETF rat model in which we provide evidence of its beneficial metabolic effects. RNA-Seq gene expression analysis was carried out on resistance vessels of the soleus, gastrocnemius, and diaphragm muscles as well as on aortic endothelial cell scrapes. Contrary to our hypothesis, the major finding of this study is that metformin produced markedly divergent gene expression effects across the different vascular beds examined and these effects appeared to be unrelated to the mechanisms thought to be responsible for metformin's therapeutic effects. Results from GO analysis confirmed this observation.
The heterogeneous vascular effects of metformin were most evident in the number of genes differentially expressed across vessels as well as the magnitude of changes. As illustrated in Figure 2 , a noted pattern is that the effects of metformin on gene expression were largely absent in aortic endothelial cells and feed arteries (i.e. larger arteries), but apparent in the downstream arterioles that lie within the epimysium of the muscle (i.e. smaller arteries). Within the arterioles examined, another intriguing observation was that only those arterioles perfusing oxidative muscle (i.e. RG2a, S2a, D2a), and not glycolytic muscle (i.e. WG2a), appeared to manifest the effect of metformin on gene expression. However, despite metformin altering expression of genes in arterioles perfusing oxidative muscle, the amount of overlap in genes with altered expression among these three second branch order arterioles was minimal. Indeed, none of the genes differentially expressed with metformin were altered in all three arterioles of high oxidative skeletal muscle. Expression of one gene (PCM1) was increased with metformin in both the RG2a and D2a, and another gene (JAG1) was increased in both RG2a and S2a. Expression of a third gene (SYNGR3) was also modulated by metformin in both the RG2a and S2a but in opposite directions (decrease in RG2a and increase in S2a). The protein encoded by PCM1 is a component of centriolar satellites, which are electron dense granules scattered around centrosomes. This protein is thought to be required for centrosome assembly and function. The jagged 1 protein encoded by JAG1 is the ligand for the receptor notch 1. Jagged 1 signaling through notch 1 has been shown to play a role in hematopoiesis and seems to be involved in early and late stages of mammalian cardiovascular development. SYNGR3 encodes an integral membrane protein whose exact function is unclear but appears to be involved in the regulation of dopamine transporter activity. Thus, none of these three genes whose expression was ''commonly'' altered with metformin treatment appear to be linked to its established mechanisms (AMPK activation and inhibition of mitochondrial complex 1 and GPD2 [18] [19] [20] , and this apparent absence of link between genes affected by metformin and its known mechanisms was also true for the remaining differentially altered genes. It should be noted that consistent with findings from others, 26 we also found that metformin altered expression of several CYP isozymes primarily in the D2a. We were recently surprised, although to a lesser extent, by the profound heterogeneous vascular effects of exercise training. [15] [16] [17] 27 Nevertheless, the notion that the effects of exercise are not the same among skeletal muscle arteries can be reconciled with the understanding that during exercise different muscle fiber recruitment patterns exist among these skeletal muscles, thus likely contributing to this differing vascular effect of training between muscles and even within muscles. 17, 27 Perhaps more surprising was our recent finding that obesity, viewed as a condition with systemic complications, also resulted in striking heterogeneous effects among arteries examined. 24, 28, 29 Indeed, we identified 20 genes whose expression was consistently altered among 15 arteries, which represented only a $9% overlapping effect of obesity among all arteries examined. 29 In keeping with the theme that systemic interventions can produce heterogeneous spatial distribution of vascular transcriptomic effects throughout the arterial vasculature, the findings from the present study are especially remarkable. Herein we provide evidence that pharmacological treatment also evokes heterogeneous effects across the arterial tree with contrasting vascular effects not only observed between muscles but also within muscle, thus resembling our prior findings on the effects of exercise [15] [16] [17] 27 and obesity. 24, 28, 29 Fundamentally, these data support the idea that regulation of vascular gene expression in response to a given insult (e.g. obesity) or treatment (e.g. exercise, metformin) is not uniform among arteries. Although we believe findings in one artery cannot be extrapolated to other arteries, this is not yet universally accepted in the field of cardiovascular biology and medicine. It is for this reason that we expect the present findings will contribute to our increasing, but complex, understanding that arteries differentially respond to a given stimulus, even when the stimulus is pharmacological and systemically administered.
We also sought to examine the extent of overlap between the genes affected by obesity (previously published 24, 29 ) and metformin across arteries. As summarized in Table 4 , to our surprise, we noted that of the 21 genes whose expression was affected by both obesity and metformin, the effects were in the same direction on 16 of the genes. Differently put, metformin only reversed the expression of five out of 2296 genes affected by obesity across the arteries examined in the present study. We also contrasted the effects of metformin to the effects of endurance exercise previously published. 16, 17, 27 We found that nine genes were affected by both metformin and exercise and these effects were all in the same direction (Table 5) .
Despite these novel findings, some considerations should be acknowledged. First, because we studied mRNA levels from whole artery homogenates (except for scraped aortic endothelial cells), it remains unknown if differences in vascular gene expression reported herein are originating from the endothelium, smooth muscle, or adventitia. Second, protein content was not assessed in the present study; thus, it is unknown the extent to which the present vascular transcriptomic effects of metformin translate to changes at the protein level. We conclude that metformin treatment produces distinct gene expression effects throughout the arterial tree in a rat model of obesity and insulin resistance. The genes whose expression was modulated with metformin do not appear to have a clear connection with its known mechanisms of action and are not the same genes affected by obesity. While we cannot offer explanations for metformin's vascular effects based on our data, we have identified a new catalog of genes that may play a role in the cardiovascular benefits of metformin. These genes and the functional consequences of their responsiveness to metformin treatment should be the focus of future studies. Furthermore, findings from this investigation support the provocative notion that vascular gene regulation in response to oral metformin is vessel specific. 
